Continuous Glucose Monitoring Helps Control Type 2 Diabetes. Can It Also Help Reverse It?

Continuous Glucose Monitoring Helps Control Type 2 Diabetes. Can It Also Help Reverse It?Continuous glucose monitoring (CGM) is rapidly transforming the management of type 2 diabetes. Once largely confined to insulin-treated patients, it is increasingly being used across the broader spectrum of diabetes care. Yet an important clinical question remains unanswered.Does CGM merely improve glycaemic control, or can it actually help reverse type 2 diabetes?In this episode, Professor Pandiyan Natarajan examines this important distinction and reviews the current scientific evidence supporting both claims.The evidence that CGM improves glucose control is now compelling. Multiple randomized controlled trials, together with recent meta-analyses, consistently demonstrate improvements in HbA1c when compared with conventional finger-stick blood glucose monitoring.But CGM has no direct pharmacological effect.Unlike medications that lower blood glucose chemically, CGM works differently. It transforms invisible metabolic responses into immediate, personalised biological feedback.Every meal becomes an experiment.Every glucose curve becomes a lesson.Every day provides an opportunity to refine behaviour.Large personalised nutrition studies have shown that identical foods often produce very different glucose responses in different individuals. Rather than relying solely on population averages such as the glycaemic index, CGM allows patients to discover how their own bodies respond to their own meals.This continuous feedback encourages healthier food choices, better meal timing, increased physical activity and sustained behavioural change.The episode then turns to the more challenging question of diabetes remission.Landmark remission studies—including Roy Taylor’s Counterpoint Study and the DiRECT Trial—demonstrated that remission is driven primarily by sustained calorie restriction, weight loss and reduction of ectopic fat. CGM was not the therapeutic intervention responsible for remission.However, emerging evidence suggests that CGM may serve two critically important roles.First, it acts as an enabler, helping patients maintain the behavioural changes necessary for long-term weight loss and metabolic improvement.Second, it functions as a verifier, documenting remission with greater precision than intermittent glucose measurements or periodic HbA1c testing.This distinction is clinically important.CGM does not replace dietary intervention.It strengthens it.The discussion also explores additional advantages of CGM, including early detection of nocturnal and exercise-induced hypoglycaemia, improved patient engagement, and the potential for truly personalised nutritional counselling.Balanced against these benefits are important limitations. Continuous glucose monitoring may increase anxiety or excessive focus on glucose fluctuations in some individuals, reminding us that technology should reduce cognitive burden rather than increase it.The central message is both simple and evidence-based.CGM does not reverse type 2 diabetes by itself.The diet does the work.Weight loss drives remission.CGM makes the biology visible.By transforming data into understanding and understanding into behaviour, continuous glucose monitoring may become one of the most powerful educational tools in modern diabetes care—not because it treats disease directly, but because it empowers patients to participate actively in their own recovery.Join Professor Pandiyan Natarajan as he explores how CGM is reshaping diabetes management, clarifies what current evidence truly supports, and discusses why behavioural feedback may prove just as important as pharmacological therapy in the future of type 2 diabetes care.